Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9801723 | 0.85 | SIGMAR1 (0.46) | SIGMAR1CHRM1CYP2D6CYP2C19KMT2A | |
| SCHEMBL9801673 | 0.85 | SIGMAR1 (0.49) | SIGMAR1CHRM1CYP2D6CYP2C19KMT2A | |
| SCHEMBL20021306 | 0.85 | SIGMAR1 (0.38) | SIGMAR1PIK3CDCYP2D6CYP2C19GAA | |
| SCHEMBL26170531 | 0.83 | PIK3CD (0.37) | SIGMAR1PIK3CDCYP2D6CYP2C19KMT2A | |
| SCHEMBL278051 | 0.81 | SIGMAR1 (0.50) | SIGMAR1CHRM1CYP2D6CYP2C19KCNJ1 | |
| SCHEMBL12942333 | 0.81 | SIGMAR1 (0.50) | SIGMAR1CHRM1CYP2D6CYP2C19KCNJ1 | |
| SCHEMBL12942334 | 0.81 | SIGMAR1 (0.50) | SIGMAR1CHRM1CYP2D6CYP2C19KCNJ1 | |
| SCHEMBL13374288 | 0.79 | SIGMAR1 (0.49) | SIGMAR1CHRM1CYP2D6CYP2C19GAA | |
| SCHEMBL19000003 | 0.76 | PIK3CD (0.40) | PIK3CDCHRM1CYP2D6 | |
| SCHEMBL19000041 | 0.76 | PIK3CD (0.40) | PIK3CDCHRM1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647678-B2 | Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-12 | — | — | US | disclosed |
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | HSF1, HSP90AB1, HSP90AB2P | SIGMAR1 3017/4885PIK3CD 1262/4885CHRM1 4131/4885 |
| US-10647678-B2 | Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity | HSF1, HSP90AB1, HSP90AB2P | SIGMAR1 3017/4885PIK3CD 1262/4885CHRM1 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.